BAX and cancer: This suggests that, although TIS deepening correlates with increased BCL-xL dependence, the requirement for mitochondrial priming varies as even minimally primed TIS cells (including BAX-deficient TIS cancer cells) can still be eliminated by BCL-xL-targeted senolytics.